We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don't just curb their desire to eat; for some, they also lead them to drink ...

That drug, now known as LOXO-305 was one of the stars of the American Society of Haematology (ASH) conference in December, finding its way into Eli Lilly ... RedX CEO Lisa Anson said the company ...

Eli Lilly has called on financial regulators to ... At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.